Concepedia

Author

A.-L. Taksin

Sorbonne Université

Also Known As

A L Taksin, A-L Taksin, A. Taksin, A.-L. Taksin, A.L Taksin, A.L. Taksin

9

Publications

594

Citations

7

H-Index

13

Concepts

All Affiliations

Sorbonne UniversitéHôpital AvicenneUniversité Sorbonne Paris NordHôpital Edouard HerriotAssistance Publique – Hôpitaux de Paris
AT

About

A.-L. Taksin is an author at Sorbonne Université specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

487

2

Hematology

3

3

417

3

Health Sciences

1

1

282

4

Pharmacology

1

1

11

5

Cancer Therapeutics

1

1

11

A.-L. Taksin

×

7

Publications

594

Citations

7

H-Index

YearCitations

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux,

Leukemia

2006

282

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret,

Leukemia

2015

120

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

V. Leblond, T Ben-Othman, Éric Deconinck,

Journal of Clinical Oncology

1998

88

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity

C. Charbonnel, R. Convers-Domart, Sophie Rigaudeau,

Annales de Cardiologie et d Angéiologie

2016

59

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies

Charikleia Kelaïdi, Aspasia Stamatoullas, Odile Beyne‐Rauzy,

Haematologica

2009

19

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Raphaël Itzykson, Sylvain Thépot, Odile Beyne‐Rauzy,

Leukemia Research

2011

15

Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia

Xavier Thomas, Nathalie Cambier, A.-L. Taksin,

Leukemia Research

2000

11

Page 1